Page last updated: 2024-08-21

pyrazines and Melanoma

pyrazines has been researched along with Melanoma in 52 studies

Research

Studies (52)

Timeframe	Studies, this research(%)	All Research%
pre-1990	1 (1.92)	18.7374
1990's	0 (0.00)	18.2507
2000's	19 (36.54)	29.6817
2010's	29 (55.77)	24.3611
2020's	3 (5.77)	2.80

Authors

Authors	Studies
Deng, JJ; Fan, G; Ge, Y; Huang, J; Liu, L; Song, Z; Xiong, XF	1
Aasen, SN; Bjørnstad, OV; Haan, C; Herdlevær, CF; Hoang, T; Preis, J; Reigstad, A; Rigg, E; Sundstrøm, T; Thorsen, F	1
Bürkel, F; Distel, L; Fietkau, R; Hecht, M; Heinzerling, L; Jost, T	1
Elmquist, WF; Gampa, G; Kim, M; Mladek, AC; Mohammad, AS; Parrish, KE; Sarkaria, JN	1
Abu-Odeh, R; Al-Qawasmeh, RA; Al-Tel, TH; Chouaib, S; El-Awady, R; Saber-Ayad, M; Semreen, MH; Voelter, W	1
Bonkobara, M; Hiroi, T; Ito, K; Iwata, T; Kobayashi, M; Kuroki, S; Kuroki, T; Mori, K; Nakagawa, T; Ono, K; Ozawa, Y; Sasaki, Y; Tetsuka, M; Washizu, T; Yamamoto, H	1
Reisman, SA	1
Brooks, TR; Carson, WE; Dao, TV; Grignol, VP; Hade, EM; Kendra, KL; Kondalasula, SV; Lesinski, GB; Luedke, EA; Markowitz, J; Mundy-Bosse, BL; Olencki, T; Paul, BK	1
Bloomfield, CD; Carson, WE; de la Chapelle, A; Eisfeld, AK; Hoag, KW; Huang, X; Jarvinen, TM; Leffel, B; Marcucci, G; Markowitz, J; Patel, R; Perrotti, D; Santhanam, R; Schwind, S; Walker, CJ	1
Ashton, G; Brognard, J; Carragher, N; Davies, L; Ejiama, S; Fish, L; Frame, M; Fusi, A; Girotti, MR; Hohloch, J; Johnson, L; Lopes, F; Lorigan, P; Macleod, K; Marais, R; Marusiak, AA; McLeary, R; Menard, D; Niculescu-Duvaz, D; Pedersen, M; Preece, N; Sanchez-Laorden, B; Saturno, G; Springer, C; Suijkerbuijk, BM; Viros, A; Whittaker, S; Zambon, A	1
Flaherty, KT	1
Aleksic, T; Asher, R; Bridges, E; Gao, S; Kamdoum, WP; Li, JL; Macaulay, VM; Margison, GP; Middleton, MR; Pfister, SX; Ramcharan, R; Repapi, E; Tanner, J; Watson, AJ; Woodcock, M	1
Baska, F; Boros, S; Dobos, J; Garamvölgyi, R; Illyés, E; Kékesi, L; Kéri, G; Őrfi, L; Sipos, A; Szabadkai, I; Szántai-Kis, C	1
Armstrong, JL; Birch-Machin, MA; Brown, AM; Corazzari, M; Hill, D; Lovat, PE; Martin, S; Pagliarini, V; Piacentini, M; Redfern, CP	1
Bouchard, P; Brown, L; Carson, WE; Chaudhury, AR; Go, MR; Guenterberg, K; Guttridge, DC; Hade, E; Ladner, KJ; Lesinski, GB; Lewis, A; Quimper, M; Raig, ET; Shah, NN; Young, G	1
Erin, N; Yerlikaya, A	1
Armstrong, JL; Birch-Machin, MA; Flockhart, R; Hill, DS; Lovat, PE; Martin, S; Redfern, CP; Simpson, DG; Tonison, JJ	1
Benninger, K; Carson, WE; Kreiner, M; Lesinski, GB; Quimper, M; Young, G	1
Baritaki, S; Berenson, J; Bonavida, B; Palladino, M; Yeung, K	1
Amschler, K; Erpenbeck, L; Pletz, N; Schön, M; Schön, MP; Wallbrecht, K	1
Amiri, KI; Ayers, GD; Horton, LW; Kelley, MC; Koehler, E; Puzanov, I; Richmond, A; Sosman, JA; Su, Y; Yu, Y	1
Blaskovits, FM; Carson, WE; Chan, AN; Grignol, VP; Guenterberg, KD; Lesinski, GB; Mundy, BL; Nuovo, GJ; Raig, ET; Young, GS; Zimmerer, JM	1
Abken, H; Brinkmann, K; Coutelle, O; Hombach, AA; Kashkar, H; Krönke, M; Mauch, C; Schmidt, P; Seeger, JM; Wagner-Stippich, D; Zigrino, P	1
Blank, JL; Burkhardt, AL; Chen, S; Chen, W; Driscoll, DL; Garcia, K; Gray, J; Hales, P; Leroy, PJ; Lightcap, ES; Lingaraj, T; Liu, XJ; Menon, S; Morgenstern, JP; Peters, T; Pickard, MD; Rabino, C; Rappoli, DM; Ringeling, J; Sappal, DS; Spelman, JJ; Yu, J	1
Anichini, A; Bolognesi, M; Delia, D; Drago, C; Kashkar, H; Lecis, D; Manzoni, L; Mastrangelo, E; Scolastico, C; Seneci, P; Walczak, H	1
Armstrong, JL; Birch-Machin, M; Fulda, S; Harbottle, A; Hill, DS; Hiscutt, EL; Kerr, R; Lovat, PE; Martin, S; Redfern, CP	1
Birch-Machin, MA; Hill, DS; Lovat, PE; Martin, S; Paton, AW; Paton, JC; Redfern, CP	1
Albertini, M; Croghan, GA; Eckardt, J; Erlichman, C; Flaherty, L; Linette, G; Ma, C; Maples, WJ; Markovic, SN; Suman, VJ	1
Al Sabah, S; Armstrong, JL; Corazzari, M; Ellis, N; Falasca, L; Fimia, GM; Hill, DS; Lovat, PE; Martin, S; Pagliarini, V; Piacentini, M; Redfern, CP	1
Abal, L; Casanova, JM; Dolcet, X; Egido, R; Llombart-Cussac, A; Martí, RM; Matias-Guiu, X; Moreno, S; Puig, S; Santacana, M; Sorolla, A; Valls, J; Velasco, A; Vilella, R; Yeramian, A	1
Chang, HC; De La Rosa, M; Han, L; Lupov, IP; Oza, K; Pelloso, D; Robertson, MJ; Sahu, RP; Schwartz, A; Travers, JB; Voiles, L	1
Cochran, MC; Eisenbrey, JR; Oum, KL; Wheatley, MA	1
Finke, J; Houet, L; Moeller, I; Spagnoli, GC; Veelken, H	1
Balivada, S; Basel, MT; Bossmann, SH; Kalita, M; Moore, D; Pyle, M; Rachakatla, RS; Seo, GM; Shinogle, H; Shrestha, TB; Thapa, PS; Troyer, DL; Villanueva, D; Wang, H	1
Bornfeld, N; Freistuehler, M; Hilger, RA; Scheulen, M; Steuhl, KP; Westekemper, H	1
Ahmad, M; Badura, HE; El-Khattouti, A; Ghanjati, F; Haikel, Y; Hassan, M; Porzig, BB; Santourlidis, S; Selimovic, D	1
Birdsell, CA; Crosby, NA; Ernstoff, MS; Poklepovic, A; Ramakrishnan, V; Roberts, JD; Winning, M; Youseffian, L; Youssefian, LE	1
Amiri, KI; Horton, LW; LaFleur, BJ; Richmond, A; Sosman, JA	1
Adjei, AA; Albertini, M; Dawkins, F; Erlichman, C; Fitch, T; Fracasso, PM; Geyer, SM; Lorusso, P; Maples, W; Markovic, SN; Sharfman, W	1
Bennett, F; Bodner, B; Bonish, BK; Chaturvedi, V; Hendrix, MJ; Miele, L; Nickoloff, BJ; Pollock, PM; Qin, JZ; Rizzo, P; Stennett, L; Trent, JM; Ziffra, J	1
Fernández, Y; Lowe, SW; Miller, TP; Opipari, AW; Rush, JL; Soengas, MS; Steiner, P; Verhaegen, M	1
Bengston, AL; Denoyelle, C; Esteban, JA; Fernández, Y; Miller, TP; Soengas, MS; Tang, WH	1
Denning, MF; Nickoloff, BJ; Qin, JZ; Sitailo, LA; Xin, H	1
Acoca, S; Beauparlant, P; Bélec, L; Billot, X; Cluse, L; Goulet, D; Johnstone, RW; Marcellus, RC; Murthy Madiraju, SR; Nguyen, M; Purisima, E; Roulston, A; Serfass, L; Shore, GC; Viallet, J; Watson, M; Wiegmans, A	1
Chinnaiyan, AM; Fernandez, Y; Gratchouck, V; Jakubowiak, AJ; Nikiforov, MA; Riblett, M; Soengas, MS; Tang, WH; Varambally, S; Verhaegen, M; Zhuang, D	1
Casanova, JM; Dolcet, X; Egido, R; Llobet, D; Llombart, A; Marti, RM; Matias-Guiu, X; Pérez de Santos, AM; Schoenenberger, JA; Soria, X; Sorolla, A; Vilella, R; Yeramian, A	1
Fuchs, SY	1
Chimirri, A; Fenech, G; Grasso, S; Monforte, P	1
Ansari, RH; Kugler, JW; Richards, JM; Ryan, CW; Shulman, KL; Sosman, JA; Vogelzang, NJ; Vokes, EE	1
Didolkar, MS; Eckardt, JR; Flaherty, LE; Samlowski, W; Sondak, VK; Taylor, SA; Unger, JM; Whitehead, RP	1
Chapman, RA; Doolittle, GC; Flaherty, LE; Hammond, N; Klein, CE; Kraut, EH; Mills, GM; Sondak, VK; Unger, JM; Whitehead, RP	1

Trials

8 trial(s) available for pyrazines and Melanoma

Article	Year
A phase I trial of bortezomib and interferon-α-2b in metastatic melanoma. Journal of immunotherapy (Hagerstown, Md. : 1997), 2014, Volume: 37, Issue:1 Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Cytokines; Female; Humans; Interferon alpha-2; Interferon-alpha; Leukocytes, Mononuclear; Male; Melanoma; Middle Aged; Neoplasm Metastasis; Neoplasm Staging; Pyrazines; Recombinant Proteins; Treatment Outcome	2014
A phase I trial of bortezomib with temozolomide in patients with advanced melanoma: toxicities, antitumor effects, and modulation of therapeutic targets. Clinical cancer research : an official journal of the American Association for Cancer Research, 2010, Jan-01, Volume: 16, Issue:1 Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Chemokines; Dacarbazine; Drug Administration Schedule; Female; Humans; Male; Melanoma; Middle Aged; NF-kappa B; Proteasome Endopeptidase Complex; Proteasome Inhibitors; Pyrazines; Skin Neoplasms; Temozolomide; Treatment Outcome	2010
A study of paclitaxel, carboplatin, and bortezomib in the treatment of metastatic malignant melanoma: a phase 2 consortium study. Cancer, 2010, Jul-15, Volume: 116, Issue:14 Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Carboplatin; Disease-Free Survival; Drug Administration Schedule; Early Termination of Clinical Trials; Female; Humans; Male; Melanoma; Middle Aged; Neoplasm Metastasis; Paclitaxel; Pyrazines; Skin Neoplasms	2010
Phase I trial of bortezomib and dacarbazine in melanoma and soft tissue sarcoma. Investigational new drugs, 2013, Volume: 31, Issue:4 Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Dacarbazine; Dose-Response Relationship, Drug; Female; Humans; Lung Neoplasms; Male; Medication Adherence; Melanoma; Middle Aged; Pyrazines; Radiography; Sarcoma; Treatment Outcome; Young Adult	2013
A phase II study of bortezomib in the treatment of metastatic malignant melanoma. Cancer, 2005, Jun-15, Volume: 103, Issue:12 Topics: Adult; Aged; Antineoplastic Agents; Boronic Acids; Bortezomib; Disease Progression; Disease-Free Survival; Female; Humans; Male; Maximum Tolerated Dose; Melanoma; Middle Aged; Proteasome Inhibitors; Pyrazines; Skin Neoplasms; Survival Rate; Treatment Failure	2005
CI-980 in advanced melanoma and hormone refractory prostate cancer. Investigational new drugs, 2000, Volume: 18, Issue:2 Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carbamates; Drug Resistance, Neoplasm; Female; Humans; Male; Melanoma; Middle Aged; Prostatic Neoplasms; Pyrazines; Pyridines	2000
Phase II trial of CI-980 in patients with disseminated malignant melanoma and no prior chemotherapy. A Southwest Oncology Group study. Investigational new drugs, 2001, Volume: 19, Issue:3 Topics: Adult; Aged; Antineoplastic Agents; Carbamates; Drug Administration Schedule; Female; Humans; Male; Melanoma; Middle Aged; Pyrazines; Pyridines; Skin Neoplasms; Survival Rate; Treatment Outcome	2001
A phase II trial of pyrazine diazohydroxide in patients with disseminated malignant melanoma and no prior chemotherapy--Southwest Oncology Group study. Investigational new drugs, 2002, Volume: 20, Issue:1 Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Female; Humans; Injections, Intravenous; Male; Melanoma; Middle Aged; Pyrazines	2002

Other Studies

44 other study(ies) available for pyrazines and Melanoma

Article	Year
Synthesis and evaluation of imidazo[1,2-a]pyrazine derivatives as small molecule Gαq/11 inhibitors against uveal melanoma. European journal of medicinal chemistry, 2022, Sep-05, Volume: 239 Topics: Cell Line, Tumor; Humans; Melanoma; Pyrazines; Uveal Neoplasms	2022
CCT196969 effectively inhibits growth and survival of melanoma brain metastasis cells. PloS one, 2022, Volume: 17, Issue:9 Topics: Brain Neoplasms; Cell Line, Tumor; Drug Resistance, Neoplasm; Humans; Melanoma; Mutation; Neoplasm Recurrence, Local; Phenylurea Compounds; Protein Kinase Inhibitors; Proto-Oncogene Proteins B-raf; Pyrazines	2022
Dual mTOR/DNA-PK Inhibitor CC-115 Induces Cell Death in Melanoma Cells and Has Radiosensitizing Potential. International journal of molecular sciences, 2020, Dec-07, Volume: 21, Issue:23 Topics: Cell Death; Cell Line; Cell Line, Tumor; DNA-Activated Protein Kinase; Fibroblasts; Homologous Recombination; Humans; Melanoma; Protein Kinase Inhibitors; Pyrazines; Radiation Tolerance; TOR Serine-Threonine Kinases; Triazoles	2020
Brain Distribution and Active Efflux of Three panRAF Inhibitors: Considerations in the Treatment of Melanoma Brain Metastases. The Journal of pharmacology and experimental therapeutics, 2019, Volume: 368, Issue:3 Topics: Animals; Brain; Brain Neoplasms; Cell Line, Tumor; Dogs; Dose-Response Relationship, Drug; Female; Heterocyclic Compounds, 3-Ring; Humans; Madin Darby Canine Kidney Cells; Male; Melanoma; Mice; Mice, Knockout; Phenylurea Compounds; Phosphatidylethanolamine Binding Protein; Pyrazines; Pyrimidines	2019
Tandem multicomponent reactions toward the design and synthesis of novel antibacterial and cytotoxic motifs. Current medicinal chemistry, 2013, Volume: 20, Issue:11 Topics: Anti-Bacterial Agents; Antineoplastic Agents; Bacteria; Bacterial Infections; Breast Neoplasms; Cell Line, Tumor; Female; Humans; Imidazoles; Melanoma; Pyrazines; Pyridines	2013
The proteasome inhibitor bortezomib inhibits the growth of canine malignant melanoma cells in vitro and in vivo. Veterinary journal (London, England : 1997), 2013, Volume: 198, Issue:3 Topics: Animals; Boronic Acids; Bortezomib; Cell Line, Tumor; Cell Proliferation; Dog Diseases; Dogs; Melanoma; Melanoma, Cutaneous Malignant; NF-kappa B; Proteasome Inhibitors; Pyrazines; Signal Transduction; Skin Neoplasms	2013
Bortezomib: a therapeutic resource for the veterinary oncologist? Veterinary journal (London, England : 1997), 2013, Volume: 198, Issue:3 Topics: Animals; Boronic Acids; Bortezomib; Dog Diseases; Melanoma; Melanoma, Cutaneous Malignant; NF-kappa B; Proteasome Inhibitors; Pyrazines; Signal Transduction; Skin Neoplasms	2013
Intronic miR-3151 within BAALC drives leukemogenesis by deregulating the TP53 pathway. Science signaling, 2014, Apr-15, Volume: 7, Issue:321 Topics: Animals; Apoptosis; Boronic Acids; Bortezomib; Cell Line, Tumor; Chromosomes; Computational Biology; Core Binding Factor Alpha 2 Subunit; Cytogenetics; Gene Expression Profiling; Gene Expression Regulation, Leukemic; Humans; Introns; Leukemia, Myeloid, Acute; Male; Melanoma; Mice; Mice, Inbred NOD; Mice, SCID; MicroRNAs; Neoplasm Proteins; NF-kappa B; Phenotype; Pyrazines; RNA, Messenger; Tumor Suppressor Protein p53	2014
Paradox-breaking RAF inhibitors that also target SRC are effective in drug-resistant BRAF mutant melanoma. Cancer cell, 2015, Jan-12, Volume: 27, Issue:1 Topics: Animals; Antineoplastic Agents; Cell Line, Tumor; Drug Resistance, Neoplasm; Female; Gene Expression Regulation, Neoplastic; Humans; Melanoma; Melanoma, Experimental; Mice; Mice, Nude; Phenylurea Compounds; Protein Kinase Inhibitors; Proto-Oncogene Proteins B-raf; Pyrazines; src-Family Kinases; Xenograft Model Antitumor Assays	2015
Effectively targeting CRAF: rational serendipity targeting SRC? Pigment cell & melanoma research, 2015, Volume: 28, Issue:3 Topics: Animals; Antineoplastic Agents; Drug Resistance, Neoplasm; Female; Humans; Melanoma; Phenylurea Compounds; Protein Kinase Inhibitors; Proto-Oncogene Proteins B-raf; Pyrazines; src-Family Kinases	2015
IGF-1R inhibition induces schedule-dependent sensitization of human melanoma to temozolomide. Oncotarget, 2015, Nov-24, Volume: 6, Issue:37 Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Blotting, Western; Cell Line, Tumor; Cell Survival; Dacarbazine; DNA Breaks, Double-Stranded; Drug Administration Schedule; Drug Resistance, Neoplasm; Drug Synergism; G1 Phase Cell Cycle Checkpoints; Humans; Imidazoles; Melanoma; Mice, Inbred BALB C; Mice, Nude; Mutation; Proto-Oncogene Proteins B-raf; Pyrazines; Receptor, IGF Type 1; Survival Analysis; Temozolomide; Tumor Suppressor Protein p53; Xenograft Model Antitumor Assays	2015
Design and synthesis of new imidazo[1,2-a]pyridine and imidazo[1,2-a]pyrazine derivatives with antiproliferative activity against melanoma cells. European journal of medicinal chemistry, 2016, Jan-27, Volume: 108 Topics: Antineoplastic Agents; Cell Line, Tumor; Cell Proliferation; Dose-Response Relationship, Drug; Drug Design; Drug Screening Assays, Antitumor; Humans; Imidazoles; Melanoma; Molecular Structure; Pyrazines; Pyridines; Structure-Activity Relationship	2016
Increasing melanoma cell death using inhibitors of protein disulfide isomerases to abrogate survival responses to endoplasmic reticulum stress. Cancer research, 2008, Jul-01, Volume: 68, Issue:13 Topics: Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Bacitracin; Boronic Acids; Bortezomib; Cell Death; Cell Survival; Drug Evaluation, Preclinical; Drug Synergism; Endoplasmic Reticulum; Enzyme Inhibitors; Fenretinide; Humans; Melanoma; Oxidative Stress; Protein Disulfide-Isomerases; Pyrazines; Treatment Outcome; Tumor Cells, Cultured	2008
IFN-alpha and bortezomib overcome Bcl-2 and Mcl-1 overexpression in melanoma cells by stimulating the extrinsic pathway of apoptosis. Cancer research, 2008, Oct-15, Volume: 68, Issue:20 Topics: Animals; Antineoplastic Agents; Apoptosis; Boronic Acids; Bortezomib; Carcinoma, Renal Cell; Caspase 3; Caspase 8; Fas-Associated Death Domain Protein; Humans; Interferon-alpha; Kidney Neoplasms; Melanoma; Mice; Mice, Inbred BALB C; Myeloid Cell Leukemia Sequence 1 Protein; Poly(ADP-ribose) Polymerases; Proto-Oncogene Proteins c-bcl-2; Pyrazines	2008
Differential sensitivity of breast cancer and melanoma cells to proteasome inhibitor Velcade. International journal of molecular medicine, 2008, Volume: 22, Issue:6 Topics: Antineoplastic Agents; Apoptosis; Boronic Acids; Bortezomib; Breast Neoplasms; Caspase 3; Cell Line, Tumor; Cell Proliferation; Cyclin-Dependent Kinase Inhibitor p21; Humans; Inhibitory Concentration 50; Melanoma; Protease Inhibitors; Proteasome Endopeptidase Complex; Proteasome Inhibitors; Pyrazines; Tumor Suppressor Protein p53	2008
Combining the endoplasmic reticulum stress-inducing agents bortezomib and fenretinide as a novel therapeutic strategy for metastatic melanoma. Clinical cancer research : an official journal of the American Association for Cancer Research, 2009, Feb-15, Volume: 15, Issue:4 Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Boronic Acids; Bortezomib; Cell Division; Cell Line, Tumor; Cell Survival; Drug Synergism; Endoplasmic Reticulum; Female; Fenretinide; G2 Phase; Humans; Ki-67 Antigen; Melanoma; Mice; Pyrazines	2009
Bortezomib pre-treatment prolongs interferon-alpha-induced STAT1 phosphorylation in melanoma cells. Cancer immunology, immunotherapy : CII, 2009, Volume: 58, Issue:12 Topics: Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Cell Line, Tumor; Drug Synergism; Humans; Interferon Type I; Janus Kinases; Leukocytes, Mononuclear; Melanoma; Phosphorylation; Proteasome Inhibitors; Pyrazines; Recombinant Proteins; Signal Transduction; STAT1 Transcription Factor; Up-Regulation	2009
Pivotal roles of snail inhibition and RKIP induction by the proteasome inhibitor NPI-0052 in tumor cell chemoimmunosensitization. Cancer research, 2009, Nov-01, Volume: 69, Issue:21 Topics: Adenocarcinoma; Antineoplastic Agents; Apoptosis; Blotting, Western; Boronic Acids; Bortezomib; Cisplatin; Humans; Lactones; Leupeptins; Male; Melanoma; Membrane Potential, Mitochondrial; NF-kappa B; Phosphatidylethanolamine Binding Protein; Prostatic Neoplasms; Proteasome Inhibitors; Proto-Oncogene Proteins c-raf; Pyrazines; Pyrroles; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; RNA, Small Interfering; Snail Family Transcription Factors; TNF-Related Apoptosis-Inducing Ligand; Transcription Factors; Transfection; Tumor Cells, Cultured	2009
NF-kappaB inhibition through proteasome inhibition or IKKbeta blockade increases the susceptibility of melanoma cells to cytostatic treatment through distinct pathways. The Journal of investigative dermatology, 2010, Volume: 130, Issue:4 Topics: Animals; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Boronic Acids; Bortezomib; Camptothecin; Cell Line, Tumor; Drug Resistance, Neoplasm; Drug Synergism; Gene Expression Regulation, Neoplastic; Humans; I-kappa B Kinase; Lung Neoplasms; Melanoma; Mice; NF-kappa B; Oxazines; Proteasome Endopeptidase Complex; Proteasome Inhibitors; Protein Kinase Inhibitors; Pyrazines; Pyridines; Skin Neoplasms	2010
Interleukin-29 binds to melanoma cells inducing Jak-STAT signal transduction and apoptosis. Molecular cancer therapeutics, 2010, Volume: 9, Issue:2 Topics: Apoptosis; Boronic Acids; Bortezomib; Cell Line, Tumor; Dacarbazine; Gene Expression Regulation, Neoplastic; Humans; Interferons; Interleukins; Janus Kinase 1; Melanoma; Oligonucleotide Array Sequence Analysis; Phosphorylation; Pyrazines; Signal Transduction; Skin Neoplasms; STAT Transcription Factors; Temozolomide	2010
The proteasome inhibitor bortezomib sensitizes melanoma cells toward adoptive CTL attack. Cancer research, 2010, Mar-01, Volume: 70, Issue:5 Topics: Apoptosis Regulatory Proteins; Boronic Acids; Bortezomib; Caspase 8; Cell Line, Tumor; Combined Modality Therapy; Enzyme Activation; Granzymes; Humans; Immunotherapy, Adoptive; Intracellular Signaling Peptides and Proteins; Lymphocyte Activation; Melanoma; Mitochondria; Mitochondrial Proteins; Proteasome Inhibitors; Proto-Oncogene Proteins c-bcl-2; Pyrazines; Receptors, Cell Surface; RNA, Small Interfering; T-Lymphocytes, Cytotoxic; Transfection; X-Linked Inhibitor of Apoptosis Protein	2010
Genome-wide siRNA screen for modulators of cell death induced by proteasome inhibitor bortezomib. Cancer research, 2010, Jun-01, Volume: 70, Issue:11 Topics: Antineoplastic Agents; Boronic Acids; Bortezomib; Cell Death; Colonic Neoplasms; DNA Damage; Gene Knockdown Techniques; HCT116 Cells; HeLa Cells; Humans; Intracellular Signaling Peptides and Proteins; Melanoma; Protease Inhibitors; Proteasome Inhibitors; Protein Serine-Threonine Kinases; Proto-Oncogene Proteins c-myc; Pyrazines; Ribosomes; RNA, Small Interfering; TOR Serine-Threonine Kinases; Transfection	2010
Novel SMAC-mimetics synergistically stimulate melanoma cell death in combination with TRAIL and Bortezomib. British journal of cancer, 2010, Jun-08, Volume: 102, Issue:12 Topics: Apoptosis Regulatory Proteins; Boronic Acids; Bortezomib; Caspase 8; Cell Death; Cell Line, Tumor; Down-Regulation; Drug Interactions; Drug Synergism; Gene Knockdown Techniques; Humans; Intracellular Signaling Peptides and Proteins; Melanoma; Mitochondrial Proteins; Pyrazines; TNF-Related Apoptosis-Inducing Ligand; X-Linked Inhibitor of Apoptosis Protein	2010
Targeting X-linked inhibitor of apoptosis protein to increase the efficacy of endoplasmic reticulum stress-induced apoptosis for melanoma therapy. The Journal of investigative dermatology, 2010, Volume: 130, Issue:9 Topics: Antineoplastic Agents; Apoptosis; Boronic Acids; Bortezomib; Drug Resistance, Neoplasm; Endoplasmic Reticulum; Female; Fenretinide; Gene Expression Regulation, Neoplastic; Genes, ras; Humans; In Vitro Techniques; Male; Melanoma; Middle Aged; Mutation; Nevus, Pigmented; Proto-Oncogene Proteins B-raf; Pyrazines; RNA, Small Interfering; Skin Neoplasms; Stress, Physiological; X-Linked Inhibitor of Apoptosis Protein	2010
Targeting GRP78 to enhance melanoma cell death. Pigment cell & melanoma research, 2010, Volume: 23, Issue:5 Topics: Antineoplastic Agents; Boronic Acids; Bortezomib; Cell Death; Cell Line, Tumor; Endoplasmic Reticulum; Endoplasmic Reticulum Chaperone BiP; Fenretinide; Heat-Shock Proteins; Humans; Melanoma; Pyrazines; RNA, Small Interfering; Unfolded Protein Response	2010
Oncogenic B-RAF signaling in melanoma impairs the therapeutic advantage of autophagy inhibition. Clinical cancer research : an official journal of the American Association for Cancer Research, 2011, Apr-15, Volume: 17, Issue:8 Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Autophagy; Biphenyl Compounds; Blotting, Western; Boronic Acids; Bortezomib; Cell Line, Tumor; Endoplasmic Reticulum; Female; Fenretinide; Humans; Luminescent Proteins; Melanoma; Mice; Microscopy, Fluorescence; Microtubule-Associated Proteins; Nitrophenols; Piperazines; Proto-Oncogene Proteins B-raf; Pyrazines; RNA Interference; Signal Transduction; Sulfonamides; Xenograft Model Antitumor Assays	2011
Inhibition of activated receptor tyrosine kinases by Sunitinib induces growth arrest and sensitizes melanoma cells to Bortezomib by blocking Akt pathway. International journal of cancer, 2012, Feb-15, Volume: 130, Issue:4 Topics: Antineoplastic Agents; Boronic Acids; Bortezomib; Cell Line, Tumor; Cell Proliferation; Chromones; Humans; Indoles; Melanoma; Morpholines; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-akt; Pyrazines; Pyrroles; Receptor Protein-Tyrosine Kinases; Receptor, Platelet-Derived Growth Factor alpha; RNA, Small Interfering; Signal Transduction; Sunitinib; Vascular Endothelial Growth Factor Receptor-2	2012
Acquired STAT4 deficiency as a consequence of cancer chemotherapy. Blood, 2011, Dec-01, Volume: 118, Issue:23 Topics: Animals; Antineoplastic Agents; Antineoplastic Agents, Alkylating; Antineoplastic Agents, Phytogenic; Boronic Acids; Bortezomib; Carmustine; Cells, Cultured; Drug Interactions; Etoposide; Flow Cytometry; Gene Expression; Humans; Interleukin-12; Interleukin-2; Leukocytes, Mononuclear; Lymphoma; Melanoma; Mice; Mice, Inbred C57BL; Protein Biosynthesis; Pyrazines; RNA Stability; Skin Neoplasms; STAT4 Transcription Factor; Ubiquitin	2011
Cellular signal transduction can be induced by TRAIL conjugated to microcapsules. Journal of biomedical materials research. Part A, 2012, Volume: 100, Issue:10 Topics: Annexin A5; Apoptosis; Boronic Acids; Bortezomib; Capsules; Cell Line, Tumor; Contrast Media; Doxorubicin; Flow Cytometry; Humans; Lactic Acid; Melanoma; Membranes, Artificial; Particle Size; Polyesters; Polymers; Pyrazines; Signal Transduction; Staining and Labeling; TNF-Related Apoptosis-Inducing Ligand; Ultrasonics	2012
Uptake routes of tumor-antigen MAGE-A3 by dendritic cells determine priming of naïve T-cell subtypes. Cancer immunology, immunotherapy : CII, 2012, Volume: 61, Issue:11 Topics: Antigen-Antibody Complex; Antigens, Neoplasm; Antineoplastic Agents; Apoptosis; Boronic Acids; Bortezomib; CD4-Positive T-Lymphocytes; CD8-Positive T-Lymphocytes; Cell Line, Tumor; Dendritic Cells; Gamma Rays; Humans; Melanoma; Multiple Myeloma; Neoplasm Proteins; Pinocytosis; Pyrazines; Skin Neoplasms; Treatment Outcome	2012
Stem cell-based photodynamic therapy. Photochemical & photobiological sciences : Official journal of the European Photochemistry Association and the European Society for Photobiology, 2012, Volume: 11, Issue:7 Topics: Aminolevulinic Acid; Animals; Cell Line, Tumor; Cell Survival; Female; Fetal Blood; Imidazoles; Luciferases; Lung Neoplasms; Melanoma; Mice; Mice, Inbred C57BL; Neural Stem Cells; Oxidation-Reduction; Photochemotherapy; Photosensitizing Agents; Plasmids; Protoporphyrins; Pyrazines; Rats; Stem Cell Transplantation; Stem Cells; Transfection	2012
Chemosensitivity of conjunctival melanoma cell lines to target-specific chemotherapeutic agents. Graefe's archive for clinical and experimental ophthalmology = Albrecht von Graefes Archiv fur klinische und experimentelle Ophthalmologie, 2013, Volume: 251, Issue:1 Topics: Antineoplastic Agents; Benzophenones; Boronic Acids; Bortezomib; Cell Proliferation; Conjunctival Neoplasms; Drug Screening Assays, Antitumor; Humans; Melanoma; Niacinamide; Phenylurea Compounds; Pyrazines; Ribonucleases; Sorafenib; Tumor Cells, Cultured	2013
Bortezomib/proteasome inhibitor triggers both apoptosis and autophagy-dependent pathways in melanoma cells. Cellular signalling, 2013, Volume: 25, Issue:1 Topics: Antineoplastic Agents; Apoptosis; Autophagy; Boronic Acids; Bortezomib; Calcium; Caspase 3; Cell Line, Tumor; Endoplasmic Reticulum Stress; HSP70 Heat-Shock Proteins; Humans; MAP Kinase Kinase Kinase 5; Melanoma; Membrane Potential, Mitochondrial; Microtubule-Associated Proteins; Mitochondria; Myeloid Cell Leukemia Sequence 1 Protein; Proteasome Inhibitors; Proto-Oncogene Protein c-ets-1; Proto-Oncogene Proteins c-bcl-2; Pyrazines; Reactive Oxygen Species; RNA Interference; RNA, Small Interfering; Signal Transduction	2013
News & views in ... Immunotherapy. Immunotherapy, 2012, Volume: 4, Issue:12 Topics: Allergens; Animals; Antineoplastic Agents; Boronic Acids; Bortezomib; Cattle; Female; Glycogen Storage Disease Type II; Human papillomavirus 16; Human papillomavirus 18; Humans; Hypersensitivity; Immunotherapy; Leukotriene B4; Melanoma; Milk; Milk Proteins; Papillomavirus Infections; Pyrazines; Receptors, Leukotriene B4; Skin Neoplasms; Tumor Escape; Uterine Cervical Neoplasms; Viral Vaccines	2012
Augmenting chemosensitivity of malignant melanoma tumors via proteasome inhibition: implication for bortezomib (VELCADE, PS-341) as a therapeutic agent for malignant melanoma. Cancer research, 2004, Jul-15, Volume: 64, Issue:14 Topics: Active Transport, Cell Nucleus; Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Boronic Acids; Bortezomib; Cell Division; Cell Line, Tumor; Dacarbazine; Drug Synergism; Female; Gene Expression; Humans; Melanoma; Mice; Mice, Inbred BALB C; Neovascularization, Pathologic; NF-kappa B; Protease Inhibitors; Pyrazines; Temozolomide	2004
Proteasome inhibitors trigger NOXA-mediated apoptosis in melanoma and myeloma cells. Cancer research, 2005, Jul-15, Volume: 65, Issue:14 Topics: Animals; Apoptosis; Boronic Acids; Bortezomib; Female; Humans; Melanocytes; Melanoma; Mice; Mice, Nude; Mitochondria; Multiple Myeloma; Oligonucleotides, Antisense; Protease Inhibitors; Proteasome Inhibitors; Proto-Oncogene Proteins c-bcl-2; Pyrazines; RNA, Messenger; Tumor Suppressor Protein p53; Xenograft Model Antitumor Assays	2005
Differential regulation of noxa in normal melanocytes and melanoma cells by proteasome inhibition: therapeutic implications. Cancer research, 2005, Jul-15, Volume: 65, Issue:14 Topics: Animals; Antineoplastic Agents; Apoptosis; Boronic Acids; Bortezomib; Caspases; Cisplatin; Cytochromes c; Doxorubicin; Drug Resistance, Neoplasm; Enzyme Activation; Female; Humans; Melanocytes; Melanoma; Mice; Mice, Nude; NF-kappa B; Protease Inhibitors; Proteasome Inhibitors; Proto-Oncogene Proteins c-bcl-2; Pyrazines; RNA Interference; Up-Regulation; Xenograft Model Antitumor Assays	2005
Chemical blockage of the proteasome inhibitory function of bortezomib: impact on tumor cell death. The Journal of biological chemistry, 2006, Jan-13, Volume: 281, Issue:2 Topics: 1,2-Dihydroxybenzene-3,5-Disulfonic Acid Disodium Salt; Antineoplastic Agents; Antioxidants; Binding, Competitive; Boronic Acids; Bortezomib; Breast Neoplasms; Cell Death; Cell Line; Cell Line, Tumor; Cell Survival; Drug Antagonism; Fibroblasts; Free Radicals; Humans; Immunoblotting; Kinetics; Leupeptins; Melanocytes; Melanoma; Membrane Potentials; Models, Biological; Protease Inhibitors; Proteasome Inhibitors; Pyrazines; Reactive Oxygen Species; Skin; Time Factors	2006
Enhanced killing of melanoma cells by simultaneously targeting Mcl-1 and NOXA. Cancer research, 2006, Oct-01, Volume: 66, Issue:19 Topics: Antineoplastic Agents; Apoptosis; bcl-2 Homologous Antagonist-Killer Protein; bcl-2-Associated X Protein; Boronic Acids; Bortezomib; Cell Line, Tumor; Drug Screening Assays, Antitumor; Drug Synergism; Humans; Melanoma; Myeloid Cell Leukemia Sequence 1 Protein; Neoplasm Proteins; Protease Inhibitors; Protein Interaction Mapping; Proto-Oncogene Proteins c-bcl-2; Pyrazines; RNA, Small Interfering; Ultraviolet Rays; Vidarabine	2006
Small molecule obatoclax (GX15-070) antagonizes MCL-1 and overcomes MCL-1-mediated resistance to apoptosis. Proceedings of the National Academy of Sciences of the United States of America, 2007, Dec-04, Volume: 104, Issue:49 Topics: Animals; Antineoplastic Agents; Apoptosis; bcl-2 Homologous Antagonist-Killer Protein; Boronic Acids; Bortezomib; Cell Line, Tumor; Cysteine Proteinase Inhibitors; Drug Resistance, Neoplasm; Humans; Indoles; Melanoma; Mice; Mitochondria; Myeloid Cell Leukemia Sequence 1 Protein; Neoplasm Proteins; Proteasome Inhibitors; Proto-Oncogene Proteins c-bcl-2; Pyrazines; Pyrroles	2007
Tumor cell-selective regulation of NOXA by c-MYC in response to proteasome inhibition. Proceedings of the National Academy of Sciences of the United States of America, 2007, Dec-04, Volume: 104, Issue:49 Topics: Antineoplastic Agents; Apoptosis; Binding Sites; Boronic Acids; Bortezomib; Drug Design; E2F1 Transcription Factor; Humans; Hypoxia-Inducible Factor 1, alpha Subunit; Melanocytes; Melanoma; Promoter Regions, Genetic; Protease Inhibitors; Proteasome Inhibitors; Proto-Oncogene Proteins c-bcl-2; Proto-Oncogene Proteins c-myc; Pyrazines; RNA Interference; RNA, Messenger; Skin Neoplasms; Transcriptional Activation; Tumor Suppressor Protein p53	2007
Effect of proteasome inhibitors on proliferation and apoptosis of human cutaneous melanoma-derived cell lines. The British journal of dermatology, 2008, Volume: 158, Issue:3 Topics: Apoptosis; Boronic Acids; Bortezomib; Cell Death; Cell Line, Tumor; Cell Proliferation; Drug Resistance, Multiple; Female; Humans; Male; Melanoma; Protease Inhibitors; Pyrazines; Skin Neoplasms; Treatment Outcome	2008
MYC-induced sensitivity of human malignant melanoma to proteasome inhibitors - a KaMYCaze effect. Pigment cell & melanoma research, 2008, Volume: 21, Issue:1 Topics: Antineoplastic Agents; Apoptosis; Boronic Acids; Bortezomib; Gene Expression Regulation, Neoplastic; Humans; Melanoma; Protease Inhibitors; Proteasome Endopeptidase Complex; Proteasome Inhibitors; Proto-Oncogene Proteins c-bcl-2; Proto-Oncogene Proteins c-myc; Pyrazines	2008
[Compounds with presumable antitumor activity. III. 1-Substituted N,N'-di-2-pyrimidinyl (or pyrazinyl)methylenediamine]. Il Farmaco; edizione scientifica, 1984, Volume: 39, Issue:9 Topics: Animals; Antineoplastic Agents; Chemical Phenomena; Chemistry; Diamines; Female; Leukemia L1210; Leukemia P388; Mammary Neoplasms, Experimental; Melanoma; Mice; Ovarian Neoplasms; Pyrazines; Pyrimidines; Rats	1984